Publications by authors named "N A Graudal"
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of abatacept and tofacitinib in treating sarcoidosis patients who were unresponsive to previous treatments.
- A total of 41 patients were treated with abatacept, while 12 received tofacitinib, with most tofacitinib patients having prior abatacept treatment.
- After 6 months, both treatments showed high drug survival rates (90% for abatacept, 89% for tofacitinib) and significant responder rates (71% and 67% respectively), indicating they are safe and effective options for patients with persistent symptoms.
Objectives: The aim of the study was to evaluate the treatment response to Interleukin-6-receptor inhibitition (IL-6Ri), primarily tocilizumab, in patients with VEXAS.
Methods: Data were obtained from review of hospital based clinical records and included symptoms, laboratory data, transfusion history, pathology reports, imaging, and treatment.
Results: Fifteen patients were treated with tocilizumab intravenously.
In this comprehensive meta-regression analysis encompassing 79 randomized controlled trials, we observed that in populations assigned to a high sodium intake level exceeding 94 mmol, there was no discernible link between plasma aldosterone levels and sodium intake. However, among populations with normal blood pressure subjected to a lower sodium intake, falling below 111 mmol (N = 1544), the association between sodium intake and plasma aldosterone levels manifested as a decrease of 192 pg/ml per 100 mmol of sodium (95% CI - 303 to - 81). In hypertensive populations (N = 1145), this association was less pronounced, with a reduction of 46 pg/ml per 100 mmol sodium, (95% CI - 112 to 20).
View Article and Find Full Text PDFImportance: This is the first network meta-analysis to assess outcomes associated with multiple conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid.
Objective: To analyze clinical outcomes after treatment with conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid among patients with rheumatoid arthritis.
Data Sources: With no time restraint, English language articles were searched in MEDLINE, Embase, Cochrane Central, ClinicalTrials.